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ABSTRACT
Objective: This study was designed to determine the efficacy and safety of Entecavir (ETV) after 96 weeks treatment in 
patients with chronic viral hepatitis B (CHB).
Methods: Thirty-eight patients were included into the study. The criteria for starting ETV treatment were as follows: 
elevated ALT levels >upper limit of normal (ULN) two times, with HBV-DNA levels ≥5 log10 copies/ml (≥20000 IU/mL), 
in HBe Ag positive patients, ≥4log10 copies/ml (≥2000IU/mL) in HBe Ag negative patients and liver damage was con-
firmed by histopathology (Knodell HAI ≥4 or fibrosis ≥1). Patients were followed up every 12 weeks by virological and 
biochemical tests. 
Results: Twenty-four of 38 patients (63.2%) were male. Mean age of patients were 38.6 years, 14 of them were HBeAg 
positive (36.8%). At baseline, median ALT level was detected as 106.7 IU/ml, median HBV DNA levels were 4.8 x 107 
copy/ml, and mean Knodell HAI score was nine. 
Eleven of 14 HBe Ag positive patients (78.6%) were treatment-naïve. No resistance mutation was determined during 
treatment. Biochemical responses (BR) at 48th and 96th week were 100% and virologic response (VR) were 57.1%, and 
50%, respectively. Serological response (SR) at 48th and 96th weeks were 35.7% and 42.8% respectively.
Fifteen (62.5%) of 24 HBe Ag negative patients were treatment-naïve; two patients were detected to have lamivudine 
resistance mutation. At 48th and 96th week, BR was 95.8%, and 100%, respectively; and VR were 83.3% both.
Conclusion: In our study, virologic response was significantly high after two years of therapy with Entecavir in HBe Ag 
negative patients. J Microbiol Infect Dis 2013;3(4): 176-180
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Kronik hepatit B hastalarında Entacavir tedavi sonuçları
ÖZET
Amaç: Bu çalışmada kronik hepatit B hastalarında 96 haftalık Entekavir (ETV) tedavi etkinliğinin ve güvenliğinin değer-
lendirilmesi amaçlandı.
Yöntemler: Kronik Hepatit B tanısıyla 38 hasta çalışmaya alındı. Entekavir tedavisine başlama kriterleri: yükselmiş ALT 
düzeyleri, (>normalin iki katında fazla), HBe Ag pozitif hastalarda HBV DNA ≥5 log10 kopya/ml (≥20000 IU/ml), HBe Ag 
negatif hastalarda ≥4 log10 kopya/ml (≥ 2000 IU/ml) karaciğer hasarının histopatolojik olarak gösterilmesi (Knodell HAİ 
≥4, fibrozis ≥1). Hastalar 12 haftada bir biyokimyasal ve virolojik testlerle takip edildi. 
Bulgular: Hastaların 24’ü (%63,2) erkekti. Yaş ortalaması 38,6 (17-67) yıldı. Tüm hastaların 14’ünde (%36,8) HBe Ag 
pozitifti. Başlangıç ortalama ALT düzeyleri 106,7 IU/ml, HBV DNA düzeyleri 4,8 x 107 kopya/ml ve Knodell HAI skoru 
dokuz idi. HBe Ag pozitif hastaların 11’i (%78,6) naivdi. Hiçbirinde direnç mutasyonu yoktu. Biyokimyasal yanıt (BY) 48. 
ve 96. haftalarda %100, virolojik yanıt (VY) sırasıyla %57,1 ve %50 idi. Serolojik yanıt (SY) sırasıyla %35,7 ve %42,8 olarak 
saptandı. HBeAg negatif hastaların 15’i (%62,5) naivdi; iki hastada lamuvidin direnç mutasyonu saptandı. Kırksekizinci ve 
96. haftalarda sırasıyla BY %95,8 ve %100, VY %83,3 saptandı.
Sonuç: Çalışmamızda iki yıllık entakavir tedavisi sonucunda, özellikle HBe Ag negatif hastalarda tedaviye yüksek oranda 
yanıt sağlanmıştır. 
Anahtar kelimeler: Kronik hepatit B, entekavir, tedaviKöse Ş, et al. Entecavir treatment in chronic hepatitis B 177
J Microbiol Infect Dis   www.jmidonline.org   Vol 3, No 4, December 2013
INTRODUCTION
Infection of HBV virus remains an important public 
health problem. Approximately 350 million people 
worldwide are chronically infected and each year is 
responsible for more than one million deaths from 
HBV associated complications.1,2 Therefore the 
principal goal of CHB therapy is to suppression of 
HBV replication in order to preventing progression 
to decompensated cirrhosis and hepatocellular car-
cinoma.3-5 
During he last two decades much progress has 
been made in treatment CHB, oral nucleos(t)ide 
analogs have been used as a new antiviral agents. 
Currently available antiviral treatment for CHB in-
cludes two immunomodulatory agents (interferon 
alpha-IFN-α,  pegylated  interferon  (peg-IFN),  and 
five  nucleos(t)ide  analogs  (lamivudine-LAM,  ad-
efovir dipivoksil-ADV, telbivudine, Entecavir (ETV), 
and tenofovir disoproksil fumarat (TDF). Among the 
nukleos(t)ide analogs, ETV and TDF are the most 
effective agents since these two drugs have shown 
superior virologic, biochemical, and histologic re-
sponse and lower rate of developing drug resistant 
mutans.6,7 Entecavir was introduced in 2007 as a 
new antiviral agent in Turkey.
Entecavir is a potent and selective guanosine 
analogue with significant activity against hepatitis 
B virus (HBV) which blocs HBV replication at three 
essential steps: primiting of the HBV polymerase, 
elongating of the DNA strand via reverse transcrip-
tion, and DNA dependent plus- strand DNA synthe-
sis and polymerization.8,9 ETV has been shown to 
have a high genetic barrier to resistance through 
five  years  of  treatment  has  been  reported  to  be 
1.2% and has been known to suppress serum HBV-
DNA to undetectable levels in 67%, 80% and 82% 
of patients after1,2 and 3 years of therapy respec-
tively.10,11
The current study was designed to determine 
the efficacy and safety of ETV after 96 weeks of 
treatment in patients CHB. 
Patients and Methods
Thirty-eight patients with diagnosis of CHB who fol-
lowed in our clinic between 2007-2010 (who were 
positive for hepatitis B surface antigen for at least 
six months) was included into the study. Patients 
who had history of alcohol ingestion, co-infection 
with  chronic  hepatitis  C  or  human  immunodefi-
ciency virus, primary biliary cirrhosis, autoimmune 
diseases, cirrhosis, hepatocellular carcinoma were 
excluded.
The criteria for starting ETV treatment were as 
follows: elevated ALT levels > upper limit of normal 
(ULN) two times, with HBV-DNA levels ≥5 log10 cop-
ies/ml (≥20000 IU/mL), in HBeAg positive patients, 
≥4 log10 copies/ml (≥2000IU/mL) in HBeAg negative 
patients and liver damage was confirmed by histo-
pathological liver examination (Knodell HAI ≥4 or 
fibrosis ≥1). 
While 36 patients with no LAM/ADV resistance 
were given Entecavir at a dose of 0.5 mg/day for 
96 week, two patients with LAM resistance received 
the drug as 1 mg/day for the same period. 
According to Association for the Fight 
Against Viral Hepatitis 2009 criteria, biochemical 
response(BR) was defined as a decrease in serum 
ALT levels to within the normal range; virological 
response(VR) was defined as a negative in serum 
HBV-DNA levels at 48th and 96th week, and a sero-
logical response(SR) was defined as a loss of se-
rum HBeAg. 
Patients were followed up every 12 weeks. Liv-
er biochemistry and AFP were measured at every 
follow-up. HBV-DNA levels and mutational analysis 
of the viral polymerase gene were determined at 
baseline and every 12 weeks.
Serum  alanine  transaminases  (ALT)  and  as-
partate transaminases (AST) were measured us-
ing an automated biochemistry analyzer. HBs Ag, 
anti HBs, HBe Ag, anti HBe, anti HBc, anti HIV, anti 
HCV, anti HDV were measured with ELISA (Liason, 
Diasory,  Italy),  HBV-DNA  was  quantified  by  real-
time polymerase chain reaction (PCR) assay (CO-
BAS  TaqMan  48,  Roche,  Branchburg,  NJ)  which 
had a lower limit of quantification of 20 copies/ml. 
The viral mutational analysis was performed by an 
reverse hybridization (Inno-LIPA HBV DR v2, Inno-
genetics, Belgium) Necro-inflammation and fibrosis 
were assessed with the Knodell histology activity 
index (HAI) scoring system.
Statistical Analysis
Data are expressed as mean ± standard deviation 
of the mean. Proportions were compared by chi-
square analysis. Mean values of two groups were 
compared by the Student’s t-test or by a nonpara-
metric test if the data were not normally distributed. 
P <0.05 was accepted as statistically significant.
RESULTS
A total of 38 patients treated with ETV included in 
the study. Twenty-four of 38 (63.2%) patients were 
male. Mean age of patients were 38.6 (range: 17-Köse Ş, et al. Entecavir treatment in chronic hepatitis B 178
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67). Twenty  six  of  patients  (68.4%)  have  not  re-
ceived previous nucleos(t)ide analogue (NA) treat-
ment  (naïve);  whereas  12  patients  (31.6%)  were 
previously received a NA. HBeAg positive patients 
constituted 36.8% of the study population. Before 
treatment only one person have normal aminotrans-
ferase level. At baseline, median ALT level was de-
tected to be 106.7 IU/ml, median HBV DNA levels 
were  4.8  x  107 copy/ml, and mean Knodell HAI 
score was nine. ALT/AST ratio and HBV DNA levels 
of patients were evaluated at 48th and 96th week. 
Eleven of HBe Ag positive patients (78.6%) 
were treatment-naïve, and 3 of them (21.4%) had 
received previously NA treatment. No resistance 
mutation was determined during treatment. Bio-
chemical  responses  (BR)  (ALT  normalization)  at 
48th and 96th week were 100% and virological re-
sponse (VR) (undetectable lowering of HBV DNA 
levels) were 57.1%, and 50%, respectively. Viro-
logical breakthrough occurred in one patient after 
treatment of 48th week. Serological responses (SR) 
(HBeAg seroconversion) at 48th and 96th week were 
35.7% and 42.8% respectively.
Fifteen (62.5%) of HBeAg negative patients 
were treatment-naïve and nine of them (37.5%) 
were given NA treatment previously; two patients 
were detected to have lamivudine resistance mu-
tation. At 48th and 96th week, BR was 95.8%, and 
100%, respectively; and VR were 83.3% both (Ta-
ble 1). Between two groups; virologic response at 
96th week was significantly high in HBeAg negative 
group. Comparison of demographic characteristics, 
baseline laboratory analysis and ETV treatment 
results at 96th week in virologic response and non-
response group has been shown at Table 2. At 96th 
week of the treatment serologic response of the 
group in which virological response has been sus-
tained was significantly higher than the non-respon-
sible group.
Table 1. Entecavir treatment results of HBeAg positive 
and negative groups
Variables
HBeAg (+)
n (%)
HBeAg (-)
n (%)
P value
Total 14 (36.8) 24 (63.2)
Mean age (years) 30±13 43±8 0.001
Female 6 (42.9) 8 (33.3) ns
Naïve 11 (78.6) 15 (62.5) ns
LAM/ADV-
resistant patient
0 2
ALT (IU/mL) 86 ± 33 118 ± 70 ns
HBVDNA
(log10 copies/ml)
9x107 ± 5.1x107 3x107 ± 3x107 <0.001
HAI (Knodell) 7.8±4.3 9.6±3.9 ns
Week 48 BR (%) 14 (100.0) 23 (95.8) ns
Week 96 BR (%) 14 (100.0) 24 (100.0) ns
Week 48 VR (%) 8 (57.1) 20 (83.3) 0.07
Week 96 VR (%) 7 (50.0) 20 (83.3) 0.03
Week 48 SR (%) 5 (35.7) - -
Week 96 SR (%) 6 (42.8) - -
Ns=not significant
Table 2. Comparison of virological response and nonre-
sponse group at 96th week
Response,
n (%)
Non-response,
n (%) P value
Total 27 (71.1) 11 (28.9)
Mean age(years) 40 ± 10 34 ± 15 ns
Female 12 (44.4) 2 (18.2) ns
Naïve 18 (72.7) 8 (66.7) ns
ALT(IU/mL) 115 ± 65 84 ± 42 ns
HBVDNA
(log10 copies/ml) 4x107 ± 5x107 6x107 ± 4x107 ns
HAI (Knodell) 8.9 ± 4.0 9.0 ± 4.5 ns
Hbe Ag (+) 7 (25.9) 7 (63.6) 0.03
Week 48 VR (%) 27 (100) 1 (9.1) -
Week 96 BR (%) 27 (100.0) - -
Week 96 SR (%) 5 (71.4) 1 (14.3) 0.03
ns=not significant
DISCUSSION
The goal of CHB treatment is to improve survival 
by preventing disease progression to decomposed 
cirrhosis, and hepatocellular carcinoma and liver re-
lated death.
Major problems in use of increasingly available 
antiviral treatment options in chronic hepatitis B are 
rebound replication upon discontinuation of treat-
ment and resistance issues. Previous studies have 
shown that Entecavir had lowest level of antiviral 
resistance compared to LAM, ADV, and telbivudine. 
Yet, since resistance to LAM and ETV may develop 
through similar mechanisms, use of Entecavir in 
LAM-resistant CHB was found to be suspicious.12,13 
Long-term  treatment  is  required  in  HBeAg 
negative CHB patients in order to provide remission Köse Ş, et al. Entecavir treatment in chronic hepatitis B 179
J Microbiol Infect Dis   www.jmidonline.org   Vol 3, No 4, December 2013
of liver disease and viral suppression. Though pe-
gylated interferon alpha offers efficacy, it has limited 
use due to its unwanted side effect profile.
In studies performed in naïve CHB patients, 
Hadziyannis et al., after a year of Entecavir treat-
ment, found virological response as 90% and bio-
chemical response as 78% in HBe Ag negative pa-
tients and 67% and 68% in HBeAg positive patients, 
respectively.14 In a study performed by Chang et al. 
comparing Entecavir and LAM treatment in naïve 
HBe Ag positive patients, virological response was 
detected as 67% and 36% in Entecavir and LAM 
arms,  respectively;  and  biochemical  response 
was found as 68% and 60% in Entecavir and LAM 
groups, respectively. Furthermore, HBe seroconver-
sion rate was 21% in Entecavir, which was 18% in 
LAM patients.15 The study by Lai et al. where Ente-
cavir and LAM were compared in naïve HBe nega-
tive CHB patients revealed that virological response 
were 90% and 72% in Entecavir and LAM groups; 
whereas biochemical response were 78% and 71% 
in these groups, respectively.16 In our study com-
prising of CHB cases treated with Entecavir for two 
years, virological response rates were detected to 
be higher in HBe Ag negative patients, compared to 
HBe Ag positive patients. We found the VR rates at 
HBe Ag positive and negative patients at week 48th 
57%, 83.3%, at week 96th 50%, 83%, respectively 
Biochemical response rates were determined to be 
high in both groups. All patients included into the 
study, serological response rates at the end of 96 
week was 42.8%, most of which consisted of na-
ïve HBe Ag positive patients. In contrast to previ-
ous studies, SR rates of our study were found to be 
higher.
Moreover, ETV studies have shown that possi-
bility of a successful outcome after long-term treat-
ment of Entecavir was low in LAM-resistant cases. 
In the study of Hadziyannis et al, while 3-year suc-
cess of Entecavir was 94% in naïve patients, it was 
detected to be 40% in LAM-resistant cases. Same 
study revealed that resistance to Entecavir after 3 
years was <1% in naïve patients although being 6% 
at the end of year 1 and 30% at the end of year 3 in 
LAM-resistant cases.14 Nagasaki et al. reported that 
3 of 4 LAM-resistant cases developed resistance 
at 52nd to 130th weeks after Entecavir treatment.13 
A German study by Tillmann et al reported that nine 
percent  of  LAM-resistant  cases  developed  resis-
tance to Entecavir after 96 week.17 In a multicenter 
study consisting of numerous LAM-resistant HBeAg 
positive CHB cases, virological and biochemical 
response rate was 4% (6/145) in the group contin-
ued to be treated with LAM for 52 weeks whereas 
it was detected to be 55% in those subjects who 
received Entecavir at a dose of 1 mg/day. While ge-
notypic resistance against Entecavir was detected 
in ten of 141 patients, 2 of them exhibited virologi-
cal rebound.18 In our study, Entecavir treatment of 
1 mg was given to 2 patients who were confirmed 
to  have  genotypic  LAM-resistance,  where  viro-
logical response after two years of treatment was 
achieved in only one patient. In our study, the treat-
ment with Entecavir resulted in increased rates of 
virologic suppression, especially in HBeAg negative 
patients. This result was found to be consistent with 
previous studies. In addition, HBeAg seroconver-
sion  rate  was  42.8%  in  HBeAg  positive  patients, 
which is higher than previous studies.19-21 In conclu-
sion, further studies with longer duration and larger 
numbers of subjects are needed to evaluate longer 
term efficacy, development of resistance, and ad-
verse effects of Entecavir.
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